prodigiosin has been researched along with mevastatin* in 1 studies
1 review(s) available for prodigiosin and mevastatin
| Article | Year |
|---|---|
Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival.
The mass and function of bones depends on the maintenance of a complicated balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. Osteoporosis typically reflects an imbalance in skeletal turnover, such that bone resorption exceeds bone formation. Osteoclasts are target cells for anti-osteoporosis therapies. To discover new types of antiresorptive agents, we screened for natural compounds that regulate osteoclast differentiation, function, and survival. As a result, we identified reveromycin A, destruxins, mevastatin, FK506, cyclosporin A, prodigiosins, concanamycins, and symbioimine among microbial natural compounds. In this review, we discuss the mechanisms of action of these compounds on osteoclasts. Topics: Animals; Apoptosis; Bacteria; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Survival; Cyclosporine; Depsipeptides; Fungi; Heterocyclic Compounds, 3-Ring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Osteoclasts; Prodigiosin; Pyrans; Spiro Compounds; Tacrolimus | 2008 |